Drugs /
os2966
Back to Drugs List
Overview
NCI Definition [1]:
A humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. Upon administration, anti-integrin beta-1 monoclonal antibody OS2966 targets and binds to integrin beta-1 on the surface of tumor cells and macrophages in the tumor microenvironment (TME), thereby preventing integrin beta-1-mediated activation of downstream signaling pathways. This may include the blockade of the binding of integrin beta-1 to the effector kinase focal adhesion kinase (FAK), preventing FAK-mediated activation of Stat1 and Akt. This may inhibit tumor cell proliferation, invasion and migration in integrin beta-1-overexpressing tumor cells. Integrin beta-1, the dominant subunit in all four classes of integrin receptors, plays an important role in tumor cell proliferation, invasion, and drug resistance.
Clinical Trials
Os2966 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating os2966, 1 is phase 1 (1 open).
Malignant glioma is the most common disease being investigated in os2966 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
